Fulcrum Therapeutics, Inc.FULCNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank38
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-60.38M
↓ 13% vs avg
Percentile
P38
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
$-53.60M
Historical baseline
PeriodValueYoY Change
TTM$-60.38M-2319.0%
2024$-2.50M+97.3%
2023$-91.47M+7.6%
2022$-99.01M-23.5%
2021$-80.19M-45.8%
2020$-55.00M-36.3%
2019$-40.34M-27.9%
2018$-31.54M-43.5%
2017$-21.98M-